What is the clinical significance of anti‑Müllerian hormone (AMH) level?

AMH Level Significance

Anti-Müllerian hormone (AMH) is a critical biomarker that reflects ovarian follicular reserve and has established clinical utility in predicting ovarian response to stimulation in assisted reproductive technology, but it is NOT currently recommended for diagnosing PCOS due to assay standardization issues and lack of validated age-specific cut-offs 1.

Primary Clinical Applications

Ovarian Reserve Assessment

AMH is secreted exclusively by granulosa cells of pre-antral and small antral follicles, making it the most accurate endocrine marker of the remaining ovarian follicle pool 1, 2. Unlike FSH and estradiol, AMH levels remain relatively stable throughout the menstrual cycle, providing a non-cyclic assessment of ovarian aging 3, 2.

Key clinical uses include:

• Predicting ovarian response to controlled ovarian stimulation: AMH outperforms age, FSH, estradiol, and inhibin B in predicting both poor response/cycle cancellation and hyper-response/ovarian hyperstimulation syndrome 4
• Fertility counseling: Low AMH levels (<1 ng/mL) are independently associated with reduced natural conception rates (adjusted hazard ratio 0.77), with the highest conception probability occurring in cycle 4 across all AMH categories 5
• Menopause prediction: AMH declines steadily with age and can predict earlier menopause onset when tracked longitudinally, though sensitivity and specificity are limited for determining exact timing 6

Assisted Reproductive Technology (ART)

AMH demonstrates superior predictive value for IVF outcomes 4, 7. Women with higher AMH levels (>2.7 ng/mL median) have significantly better clinical pregnancy rates in controlled ovarian stimulation with intrauterine insemination compared to those with lower levels (2.0 ng/mL median, p=0.005) 7.

Critical threshold effects:

• AMH >10 ng/mL correlates with higher ovarian hyperstimulation syndrome risk and increased clinical pregnancy rates 8
• AMH <1 ng/mL indicates reduced conception probability requiring earlier intervention 5

PCOS Context: Important Limitations

While AMH levels are significantly elevated in PCOS women compared to controls 1, international guidelines explicitly recommend AGAINST using AMH for PCOS diagnosis outside of research settings 1.

Why AMH cannot currently diagnose PCOS:

• Substantial overlap exists between PCOS patients and healthy controls, particularly in adolescents within 8 years of menarche 1
• Assay standardization remains problematic with significant sample-to-sample variability and between-assay conversion discrepancies 1
• No validated, internationally approved age-specific cut-offs exist 1
• In adolescents, AMH ≥4.0 ng/mL shows only 51.3% sensitivity despite 86.1% specificity, missing nearly half of PCOS cases 9

The evidence shows: Over 97% of women with ultrahigh AMH (>10 ng/mL) have PCOS, and AMH correlates positively with luteinizing hormone, testosterone, and DHEAS 8. However, this correlation does not translate to diagnostic utility without standardized assays and validated thresholds.

Primary Ovarian Insufficiency (POI)

AMH levels <8 pmol/L demonstrate 85% sensitivity and 100% specificity for diagnosing POI in women with secondary oligomenorrhea, making it valuable for distinguishing POI from other causes of amenorrhea 6.

Critical Assay Considerations

Major pitfalls to avoid:

• Older DSL and Immunotech assays are no longer marketed and show poor concordance 1
• Sample handling, transport, and storage conditions significantly impact results but are frequently under-reported 1
• Automated platform assays have limited validation data 1
• Results cannot be reliably compared across different assay platforms without conversion factors 1

Before clinical application: Ensure your laboratory uses current automated assays with proper sample handling protocols. Age-specific reference ranges are essential, as AMH varies dramatically across the lifespan and falls significantly after menopause 1, 6.

Practical Clinical Algorithm

For fertility evaluation:

1. Measure AMH using standardized automated assays with age-specific reference ranges
2. AMH <1 ng/mL → counsel regarding reduced natural conception probability; consider earlier ART referral
3. AMH 1-5.5 ng/mL → normal ovarian reserve
4. AMH >10 ng/mL → high PCOS likelihood (>97%); increased OHSS risk with stimulation

For PCOS evaluation:

• Do NOT use AMH as a diagnostic criterion 1
• Use Rotterdam criteria (2 of 3: oligo-/anovulation, hyperandrogenism, polycystic ovaries on ultrasound)
• Avoid ultrasound diagnosis within 8 years of menarche 1
• AMH may serve as adjunctive information but cannot replace established diagnostic criteria

For POI diagnosis:

• AMH <8 pmol/L supports POI diagnosis in women with oligomenorrhea 6

The fundamental limitation remains: until international assay standardization is achieved with validated age-specific cut-offs based on large-scale studies, AMH's clinical utility is restricted to ovarian reserve assessment and ART response prediction 1.